SDB-006

SDB-006
SDB-006 structure.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC21H24N2O
Molar mass320.43 g/mol g·mol−1
3D model (JSmol)

SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 19 nM for human CB2 receptors, and 134 nM for human CB1 receptors.[1][2] It was discovered during research into the related compound SDB-001 which had been sold illicitly as "2NE1".[3] SDB-006 metabolism has been described in literature.[4]

See also[edit]

References[edit]

  1. ^ Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" (PDF). ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407.
  2. ^ Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M (January 2018). "The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs". Drug Testing and Analysis. 10 (7): 1099–1109. doi:10.1002/dta.2362. PMID 29350472.
  3. ^ Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. (July 2013). "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience. 4 (7): 1081–92. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277.
  4. ^ Diao X, Carlier J, Scheidweiler KB, Huestis MA (July 2017). "In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry". Forensic Toxicology. 35 (2): 252–262. doi:10.1007/s11419-016-0350-9.